eli lilly glp 1 market share The $58B Weight Loss Drug in One Chart GLP-1 boom makes Eli Lilly

Retrieved from Pitt, R.D., Pilz, J., et al

Obes Res Clin Pract 2025;19:77-9.ArticlePubMed 99

GLP-1 receptor agonists may be considered for their FDA-approved indications glycemic control in type 2 diabetes or chronic weight management in obesitybut should not be viewed as treatments for Hashimoto's disease itself

The injectable form also has an indication to treat patients with noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advances fibrosis (stage F2 or F3)

Not only is it formulated with highly researched ingredients rooted in clinical trials, Lemme is the only brand with the exclusive on a patented bioflavonoid shown to naturally boost GLP-1 levels

While these drugs are helping many people lose excess fat and improve their health, there can be downsides to treatment